MUSK and myasthenia gravis: B-cell depletion therapy in MG is thought to act primarily by reducing the production of AChR and MuSK antibodies, thereby attenuating complement-mediated postsynaptic membrane injury, and may also facilitate recovery of NMJ transmission by modulating the immune microenvironment and local inflammatory responses at multiple levels (Chamberlain et al., 2021; San and Jacob, 2023; Cavalcante et al., 2024).